Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Melanoma Research
|
August 1, 1996
The control of gene expression in melanocytes and melanomas
T G Eisen
Oncology (Williston Park, N.Y.)
|
February 24, 2001
Thalidomide in solid tumors: the London experience
T G Eisen
Melanoma Research
|
July 26, 2002
Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest
K S M Smalley, T G Eisen
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2015
The power of phase II end-points for different possible mechanisms of action of an experimental treatment
J M S Wason, A Dentamaro, T G Eisen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma
P D Nathan, M E Gore, T G Eisen
British Journal of Cancer
|
August 12, 2004
A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma
S L Morris, S H Low, R P A'Hern, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer
R H De Boer, T G Eisen, P A Ellis, et al.
British Journal of Cancer
|
December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
J M G Larkin, S A Hughes, D A Beirne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group
R M Rudd, N H Gower, S G Spiro, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Melanoma Research
|
August 1, 1996
The control of gene expression in melanocytes and melanomas
T G Eisen
Oncology (Williston Park, N.Y.)
|
February 24, 2001
Thalidomide in solid tumors: the London experience
T G Eisen
Melanoma Research
|
July 26, 2002
Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest
K S M Smalley, T G Eisen
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2015
The power of phase II end-points for different possible mechanisms of action of an experimental treatment
J M S Wason, A Dentamaro, T G Eisen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma
P D Nathan, M E Gore, T G Eisen
British Journal of Cancer
|
August 12, 2004
A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma
S L Morris, S H Low, R P A'Hern, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer
R H De Boer, T G Eisen, P A Ellis, et al.
British Journal of Cancer
|
December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
J M G Larkin, S A Hughes, D A Beirne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group
R M Rudd, N H Gower, S G Spiro, et al.
Page
of 1